Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
41.76
+0.33 (+0.80%)
Streaming Delayed Price
Updated: 11:23 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
26
27
Next >
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
May 11, 2022
Roche isn't the only company working on an anti-TIGIT molecule.
Via
Investor's Business Daily
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
May 11, 2022
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...
Via
Benzinga
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
May 11, 2022
From
Genentech
Via
Business Wire
Market Selloff
May 10, 2022
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.
Via
Talk Markets
Roche Releases More Evrysdi Data For Very Young Infants With SMA
April 29, 2022
Via
Benzinga
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
April 29, 2022
From
Genentech
Via
Business Wire
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
April 26, 2022
Via
Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
April 25, 2022
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
Via
Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
April 25, 2022
Via
Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
April 22, 2022
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
April 20, 2022
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Via
InvestorPlace
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
April 16, 2022
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...
Via
Talk Markets
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
April 15, 2022
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.
Via
Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
April 14, 2022
Via
Benzinga
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers
April 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets...
Via
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
April 13, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
April 08, 2022
Only Medicare patients enrolled in specific studies will receive reimbursement.
Via
Investor's Business Daily
Good and Bad stock news
April 05, 2022
Microsoft is down because of an FTC investigation of its possible anti-competitive moves.
Via
Talk Markets
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
April 04, 2022
From
Genentech
Via
Business Wire
SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio
April 04, 2022
Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S....
Via
Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
April 04, 2022
Via
Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
April 04, 2022
Via
Benzinga
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From
Genentech
Via
Business Wire
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.